Imagine a groundbreaking discovery that could flip the script on one of the most debated health topics of our time—mRNA COVID-19 vaccines not only slash the risk of dying from the virus itself but might even extend lives overall. Intriguing, right? But here's where it gets controversial...
A comprehensive study examining nearly half of France's population reveals that adults aged 18 to 59 who received mRNA COVID-19 vaccines were 74% less likely to die from COVID-19 complications in a hospital setting. What's even more striking? Over the following four years, these vaccinated individuals faced a 25% lower chance of death from any cause whatsoever compared to those who remained unvaccinated.
The full details of this article are tucked away behind a paywall. To dive deeper, you'll need to sign in or subscribe for complete access.
Just last month, a controversial memo from the FDA's Center for Biologics Evaluation and Research (CBER)—which was swiftly dismissed by 12 former FDA leaders (https://www.iflscience.com/12-former-fda-heads-call-out-fdas-leaked-memo-claiming-covid-19-vaccines-killed-children-in-bid-to-change-policy-81792)—alleged 10 fatalities directly linked to mRNA COVID-19 vaccines. The memo's author, CBER director Vinayak Prasad, offered no supporting evidence or specifics for independent verification.
Yet, rigorous scientific investigations into mRNA vaccine safety have repeatedly debunked such assertions, demonstrating that vaccination is far safer for people of all ages than contracting the virus itself (https://www.iflscience.com/largest-real-world-covid-19-vaccine-study-confirms-overwhelming-safety-60785). For instance, think of it like choosing between a proven shield or risking a direct hit from a widespread threat. And this is the part most people miss: the latest research by Laura Semenzato from France's National Agency for the Safety of Medicines and Health Products stands out for two key reasons.
First, the scale is unprecedented. In regions where participants must opt-in to share vaccination and health data, gathering large datasets can be prohibitively costly. Some studies use broader regional stats, revealing higher death rates in areas with lower vaccination uptake (https://jamanetwork.com/journals/jama/fullarticle/2798990), but these can't pinpoint whether the deceased were vaccinated or not—though it makes logical sense to suspect the latter. Semenzato's team, however, tapped into France's comprehensive health database, which assigns a unique identifier to every resident, linking their vaccination records to medical outcomes. This enabled tracking 28.7 million people, with 22.8 million having received their initial mRNA COVID-19 dose between May and October 2021. Those vaccinated outside this timeframe or with non-mRNA options (which were uncommon in France) were not included, ensuring a focused analysis.
Second, the study broadened its lens to examine deaths from all causes—everything from heart disease to accidents—over a full 45 months, rather than the shorter periods like six or 12 months seen in many others. This longer view helps paint a fuller picture of long-term health impacts, much like observing a marathon instead of just the starting sprint.
Critics often argue that vaccines pose undue risks for younger folks, but this research specifically targeted those aged 18 to 59 as of November 1, 2021, avoiding skew from older, more vulnerable groups. Raw data showed vaccinated individuals had a 74% reduced risk of COVID-19-related hospital deaths. For overall mortality, 0.4% of the vaccinated group passed away after nearly four years, compared to 0.6% among the unvaccinated.
Now, skeptics might point out that these figures alone don't settle the debate. If the unvaccinated group included more people with pre-existing serious illnesses, vaccines might not be the hero here. But the data told a different story: Vaccinated folks were, on average, about a year older and slightly more often female. They also had a higher prevalence of potentially risky cardiometabolic issues at the time of vaccination—9.3% versus 7.8% for the unvaccinated. While income data wasn't directly available, residential information hinted that those in the poorest 20% of areas were somewhat less likely to vaccinate, though the gap wasn't huge.
After accounting for all these variables, the researchers determined that mRNA vaccination correlated with a 25% drop in all-cause mortality. This even includes unrelated events like car crashes or natural disasters, which vaccination status shouldn't influence. In the initial six months post-vaccination, the difference was even sharper, with vaccinated deaths 29% lower.
Of course, the vaccine's protective effects might not be the sole contributor to this disparity. We don't know why some skipped vaccination—perhaps swayed by misinformation about dangers—and factors like education remain uncharted, acting as potential hidden influences. Separating the vaccine's role from these "residual confounding factors" is tricky, but the remarkably low death rates among the vaccinated make arguments of significant vaccine risks seem increasingly far-fetched.
This finding flies in the face of sensational claims on social media that mRNA vaccines have caused millions of deaths, but it also raises eyebrows: Could broader health behaviors or unmeasured variables play a bigger part? What do you think—is this proof positive, or are we missing pieces of the puzzle? Share your thoughts in the comments below; I'd love to hear agreements, disagreements, or fresh perspectives to keep the conversation going.
The research appears in JAMA Open (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2842305).
